| Literature DB >> 24154875 |
Xiao-Mei Li1, Ali Mohammad-Djafari, Mircea Dumitru, Sandrine Dulong, Elisabeth Filipski, Sandrine Siffroi-Fernandez, Ali Mteyrek, Francesco Scaglione, Catherine Guettier, Franck Delaunay, Francis Lévi.
Abstract
Circadian timing of anticancer medications has improved treatment tolerability and efficacy several fold, yet with intersubject variability. Using three C57BL/6-based mouse strains of both sexes, we identified three chronotoxicity classes with distinct circadian toxicity patterns of irinotecan, a topoisomerase I inhibitor active against colorectal cancer. Liver and colon circadian 24-hour expression patterns of clock genes Rev-erbα and Bmal1 best discriminated these chronotoxicity classes, among 27 transcriptional 24-hour time series, according to sparse linear discriminant analysis. An 8-hour phase advance was found both for Rev-erbα and Bmal1 mRNA expressions and for irinotecan chronotoxicity in clock-altered Per2(m/m) mice. The application of a maximum-a-posteriori Bayesian inference method identified a linear model based on Rev-erbα and Bmal1 circadian expressions that accurately predicted for optimal irinotecan timing. The assessment of the Rev-erbα and Bmal1 regulatory transcription loop in the molecular clock could critically improve the tolerability of chemotherapy through a mathematical model-based determination of host-specific optimal timing. ©2013 AACR.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24154875 DOI: 10.1158/0008-5472.CAN-13-1528
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701